US CDC panel votes in favor of Merck's RSV antibody drug

(Reuters) -An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, whose mothers did not receive a preventive shot during pregnancy. U.S. Health Secretary Robert F. Kennedy Jr., who has a long history of sowing doubt about vaccine safety, this month fired